Back
Science

Immunotherapy Shows Promise for Generalized Myasthenia Gravis in New Study

Generated on: Last updated: 1 sources
View source

New Immunotherapy Shows Promise for Generalized Myasthenia Gravis

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics indicates that an immunotherapy approach may benefit individuals with generalized myasthenia gravis (gMG). Generalized myasthenia gravis is an autoimmune disease characterized by variable muscle weakness and fatigue, caused by the body attacking cells involved in nerve-muscle communication. The trial results were published in Nature Medicine.

Key Findings and Treatment

  • The study investigated Descartes-08, an mRNA-based Chimeric Antigen Receptor (CAR) T-cell therapy.
  • Descartes-08 utilizes immune cells harvested from the patient's blood to reduce the production of harmful antibodies.
  • Unlike DNA-based CAR T-cell therapies, this mRNA approach does not modify the patient's genetic material and has not been associated with serious side effects in this trial.

Clinical Trial Details

  • The blinded, multicenter, phase 2b trial involved 26 adult participants with various gMG subtypes across sites in the U.S., Canada, and Türkiye.
  • 15 participants received six weekly doses of Descartes-08, while 11 received a placebo.
  • Efficacy was assessed over twelve months using physician and participant-reported outcomes.

Promising Results and Future Implications

Approximately 57% of participants who received Descartes-08 achieved minimal symptom expression (nearly no disease symptoms) by month six, with results maintained through month twelve.

Dr. James Howard Jr. of UNC Department of Neurology, senior author of the paper, noted that this treatment could offer a valuable, brief course with long-term benefits for gMG patients. The therapy may address a gap in current gMG care, as existing medications can carry risks of infections and often require a long time for symptom improvement.

Nature Medicine recognized the Descartes-08 trial as one of the "clinical trials to watch in 2026" due to its potential impact on precision medicine and global health. Researchers believe this mRNA CAR T-cell approach could potentially extend to other autoimmune conditions such as multiple sclerosis, lupus, or rheumatoid arthritis.

A larger clinical trial is underway to further confirm these results in patients with anti-AChR antibody-positive disease, the most common gMG subtype.